Compare Deutsche Bank AG (DB) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Novartis AG — how do they compare? Deutsche Bank AG trades at $33.76 (market cap $62.42B), while Novartis AG trades at $142.98 (market cap $268.57B). The key difference: Novartis AG is far larger — about 4.3× Deutsche Bank AG's market cap, and Deutsche Bank AG pays the higher dividend (3.46%). Which is the better fit depends on your goals — on Pluang, investors hold Deutsche Bank AG for 80 Days and Novartis AG for 82 Days on average.
| DB | NVS | |
|---|---|---|
Market Cap | $62.42B | $268.57B |
Volume | 2,918,760 | 1,532,573 |
Sector | Financials | Health |
52-Week High | $41.56 | $168.62 |
52-Week Low | $28.37 | $121.80 |
Typical Hold Time | 80 Days | 82 Days |
Enterprise Value | $77.06B | $309.89B |
Dividend Yield | 3.46% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $33.55, down 4.5% on concerns about Q3 investment banking revenue. The stock shows attractive valuation metrics with P/E of 9.09 and P/B of 0.71, while fundamentals improved with 2025 net income reaching $6.93B and profit margin expanding to 21.59%. Technical indicators signal bearish momentum with the price near key support at $33. Recent news highlights the bank's strategic focus on wealth management growth and 2028 return targets.
The outlook remains balanced - strong fundamentals and undervaluation provide upside potential, but near-term headwinds in investment banking and technical weakness suggest cautious optimism. Key risks include execution on strategic targets and market-sensitive revenue streams, while analyst consensus leans neutral with 58% hold ratings.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
